TOR1A and amyotrophic lateral sclerosis: This is intriguing considering independent studies, unrelated to torsinA biology and presumably mechanistically distinct, resulted in the identification of this same class of compounds as therapeutic candidates used in human clinical trials for ALS (Rothstein et al., 2005).